CA2771087C - Use of antisecretory factors for treating intraocular hypertension - Google Patents

Use of antisecretory factors for treating intraocular hypertension Download PDF

Info

Publication number: CA2771087C
Authority: CA; Canada
Prior art keywords: pharmaceutical composition; antisecretory; iop; eye; peptide
Prior art date: 2006-04-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2771087A

Other languages

English (en)

French (fr)

Other versions

CA2771087A1 (en

Inventor

Hans-Arne Hansson

Stefan Lange

Eva Jennische

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LANTMANNEN AS-FAKTOR AB

Original Assignee

LANTMANNEN AS-FAKTOR AB

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-27

Filing date

2007-04-27

Publication date

2016-03-15

2007-04-27 Application filed by LANTMANNEN AS-FAKTOR AB filed Critical LANTMANNEN AS-FAKTOR AB

2007-11-08 Publication of CA2771087A1 publication Critical patent/CA2771087A1/en

2016-03-15 Application granted granted Critical

2016-03-15 Publication of CA2771087C publication Critical patent/CA2771087C/en

Status Expired - Fee Related legal-status Critical Current

2027-04-27 Anticipated expiration legal-status Critical

Links

230000001262 anti-secretory effect Effects 0.000 title claims abstract description 101
206010020772 Hypertension Diseases 0.000 title claims abstract description 46
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 67
238000011282 treatment Methods 0.000 claims abstract description 55
230000002265 prevention Effects 0.000 claims abstract description 15
238000004519 manufacturing process Methods 0.000 claims abstract description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 41
239000003814 drug Substances 0.000 claims description 19
230000037396 body weight Effects 0.000 claims description 16
239000000546 pharmaceutical excipient Substances 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 11
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
125000006239 protecting group Chemical group 0.000 claims description 8
239000000443 aerosol Substances 0.000 claims description 6
210000004899 c-terminal region Anatomy 0.000 claims description 6
239000006199 nebulizer Substances 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 5
230000000699 topical effect Effects 0.000 claims description 5
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
238000007920 subcutaneous administration Methods 0.000 claims description 3
238000007910 systemic administration Methods 0.000 claims description 3
238000011200 topical administration Methods 0.000 claims description 3
125000003368 amide group Chemical group 0.000 claims 1
230000004410 intraocular pressure Effects 0.000 abstract description 130
102000004169 proteins and genes Human genes 0.000 abstract description 77
108090000623 proteins and genes Proteins 0.000 abstract description 77
239000012634 fragment Substances 0.000 abstract description 47
238000013459 approach Methods 0.000 abstract description 6
210000001124 body fluid Anatomy 0.000 abstract description 2
239000010839 body fluid Substances 0.000 abstract description 2
210000001508 eye Anatomy 0.000 description 104
235000018102 proteins Nutrition 0.000 description 76
238000000034 method Methods 0.000 description 42
241001465754 Metazoa Species 0.000 description 34
241000283973 Oryctolagus cuniculus Species 0.000 description 34
235000001014 amino acid Nutrition 0.000 description 33
150000001413 amino acids Chemical class 0.000 description 33
125000003275 alpha amino acid group Chemical group 0.000 description 30
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 27
239000002953 phosphate buffered saline Substances 0.000 description 27
108010038288 antisecretory factor Proteins 0.000 description 25
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
210000002159 anterior chamber Anatomy 0.000 description 19
230000000694 effects Effects 0.000 description 19
239000012530 fluid Substances 0.000 description 19
210000001585 trabecular meshwork Anatomy 0.000 description 17
239000003981 vehicle Substances 0.000 description 16
239000000203 mixture Substances 0.000 description 15
229940079593 drug Drugs 0.000 description 13
230000009467 reduction Effects 0.000 description 13
102000002322 Egg Proteins Human genes 0.000 description 12
108010000912 Egg Proteins Proteins 0.000 description 12
230000015572 biosynthetic process Effects 0.000 description 12
230000008021 deposition Effects 0.000 description 12
235000013345 egg yolk Nutrition 0.000 description 12
210000002969 egg yolk Anatomy 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
235000013305 food Nutrition 0.000 description 11
230000033764 rhythmic process Effects 0.000 description 11
210000003462 vein Anatomy 0.000 description 11
208000010412 Glaucoma Diseases 0.000 description 10
241000282414 Homo sapiens Species 0.000 description 10
102000004196 processed proteins & peptides Human genes 0.000 description 10
102100033458 26S proteasome non-ATPase regulatory subunit 4 Human genes 0.000 description 9
101001135231 Homo sapiens 26S proteasome non-ATPase regulatory subunit 4 Proteins 0.000 description 9
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 8
230000001133 acceleration Effects 0.000 description 8
210000004087 cornea Anatomy 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
229960004605 timolol Drugs 0.000 description 8
241000124008 Mammalia Species 0.000 description 7
239000007788 liquid Substances 0.000 description 7
210000005252 bulbus oculi Anatomy 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
230000009885 systemic effect Effects 0.000 description 6
210000001760 tenon capsule Anatomy 0.000 description 6
241000282412 Homo Species 0.000 description 5
230000001886 ciliary effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
238000009825 accumulation Methods 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
210000003717 douglas' pouch Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
238000005259 measurement Methods 0.000 description 4
210000001328 optic nerve Anatomy 0.000 description 4
230000008569 process Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002207 retinal effect Effects 0.000 description 4
210000003786 sclera Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
206010030113 Oedema Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
230000004075 alteration Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000006172 buffering agent Substances 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
239000002738 chelating agent Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
230000003511 endothelial effect Effects 0.000 description 3
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
230000006870 function Effects 0.000 description 3
210000003128 head Anatomy 0.000 description 3
-1 inhalation devices Substances 0.000 description 3
208000014674 injury Diseases 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
108010068435 peptide AF-16 Proteins 0.000 description 3
230000002085 persistent effect Effects 0.000 description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
210000001747 pupil Anatomy 0.000 description 3
238000012552 review Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000002123 temporal effect Effects 0.000 description 3
230000001052 transient effect Effects 0.000 description 3
230000008733 trauma Effects 0.000 description 3
230000007306 turnover Effects 0.000 description 3
210000004127 vitreous body Anatomy 0.000 description 3
101710157236 41 kDa protein Proteins 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
201000004569 Blindness Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
208000005156 Dehydration Diseases 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
206010062767 Hypophysitis Diseases 0.000 description 2
206010067482 No adverse event Diseases 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000013543 active substance Substances 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000001949 anaesthesia Methods 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000003436 cytoskeletal effect Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
230000018044 dehydration Effects 0.000 description 2
238000006297 dehydration reaction Methods 0.000 description 2
238000005474 detonation Methods 0.000 description 2
235000013681 dietary sucrose Nutrition 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000000975 dye Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
210000002569 neuron Anatomy 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000003635 pituitary gland Anatomy 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000001603 reducing effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000001878 scanning electron micrograph Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
210000000130 stem cell Anatomy 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000003934 vacuole Anatomy 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
230000004393 visual impairment Effects 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
108010022579 ATP dependent 26S protease Proteins 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
235000006491 Acacia senegal Nutrition 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 description 1
101100084999 Caenorhabditis elegans rpn-10 gene Proteins 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
208000012184 Diffuse Brain injury Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000007157 Hydrophthalmos Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000237502 Ostreidae Species 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000282887 Suidae Species 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
210000002294 anterior eye segment Anatomy 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
229960000722 brinzolamide Drugs 0.000 description 1
201000001024 buphthalmos Diseases 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001175 calcium sulphate Substances 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004323 caveolae Anatomy 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940116592 central nervous system diagnostic radiopharmaceuticals Drugs 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
210000002987 choroid plexus Anatomy 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
206010010121 compartment syndrome Diseases 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
229960003933 dorzolamide Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000004406 elevated intraocular pressure Effects 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
230000002055 immunohistochemical effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
210000004880 lymph fluid Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
239000003595 mist Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
108091005763 multidomain proteins Proteins 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
210000005044 neurofilament Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
235000015205 orange juice Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
235000020636 oyster Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000008439 repair process Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000001360 synchronised effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005167 vascular cell Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Ophthalmology & Optometry (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Dispersion Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

CA2771087A 2006-04-27 2007-04-27 Use of antisecretory factors for treating intraocular hypertension Expired - Fee Related CA2771087C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
SE0600932		2006-04-27
SE0600932-8		2006-04-27
CA2650344A CA2650344C (en)	2006-04-27	2007-04-27	Use of antisecretory protein to treat intraocular hypertension

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2650344A Division CA2650344C (en)	2006-04-27	2007-04-27	Use of antisecretory protein to treat intraocular hypertension

Publications (2)

Publication Number	Publication Date
CA2771087A1 CA2771087A1 (en)	2007-11-08
CA2771087C true CA2771087C (en)	2016-03-15

Family

ID=38561776

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA2771087A Expired - Fee Related CA2771087C (en)	2006-04-27	2007-04-27	Use of antisecretory factors for treating intraocular hypertension
CA2650344A Expired - Fee Related CA2650344C (en)	2006-04-27	2007-04-27	Use of antisecretory protein to treat intraocular hypertension

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CA2650344A Expired - Fee Related CA2650344C (en)	2006-04-27	2007-04-27	Use of antisecretory protein to treat intraocular hypertension

Country Status (18)

Country	Link
US (2)	US8207296B2 (pl)
EP (2)	EP2468292B8 (pl)
JP (2)	JP5284948B2 (pl)
KR (1)	KR20090040404A (pl)
CN (2)	CN102633863B (pl)
AU (1)	AU2007244004B2 (pl)
BR (1)	BRPI0710959B8 (pl)
CA (2)	CA2771087C (pl)
DK (2)	DK2468292T3 (pl)
ES (2)	ES2773945T3 (pl)
IL (1)	IL194773A (pl)
MX (1)	MX2008013769A (pl)
NZ (2)	NZ572255A (pl)
PL (2)	PL2015767T3 (pl)
RU (1)	RU2458703C2 (pl)
SG (1)	SG171602A1 (pl)
WO (1)	WO2007126364A2 (pl)
ZA (1)	ZA200809115B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2015767T3 (pl) *	2006-04-27	2016-05-31	Lantmaennen As Faktor Ab	Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
US9962424B2 (en)	2007-04-27	2018-05-08	Lantmännen As-Faktor Ab	Use of antisecretory factors (AF) for optimizing cellular uptake
EP2396024A4 (en) *	2009-02-11	2013-02-27	Lantmaennen As Faktor Ab	USE OF ANTISECRREATORY FACTORS (AF) FOR OPTIMIZATION OF CELLULAR ABSORPTION
WO2013050795A1 (en) *	2011-10-03	2013-04-11	Femtonics Kft.	Use of photoactive compounds
CA3036216A1 (en) *	2012-12-20	2014-06-26	Lantmannen As-Faktor Ab	Use of antisecretory factor (af) in glioblastoma treatment
CN107949392B (zh) *	2015-07-10	2022-10-11	兰特门内阿斯-法克托尔公司	用于生产含高含量af-16的蛋黄的方法
JP6999638B2 (ja)	2016-07-18	2022-01-18	ラントメネン・メディカル・アーベー	抗分泌性因子１７
CA3103164A1 (en)	2018-06-28	2020-01-02	Lantmannen Medical Ab	Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065091A1 (en)	2018-09-28	2020-04-02	Lantmännen Functional Foods Ab	A consumable product comprising malted wheat
WO2020065089A2 (en)	2018-09-28	2020-04-02	Lantmännen Functional Foods Ab	A consumable product comprising malted dehulled oat
CN115605214A (zh)	2020-03-26	2023-01-13	兰特门内保健食品公司（Se）	用于促进身体活动恢复的包含麦芽化谷物的可消耗产品
US20240148709A1 (en) *	2022-11-08	2024-05-09	Aisa Pharma, Inc.	Methods of treating eye pain and eye disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH682716A5 (de)	1992-01-13	1993-11-15	Christian Fricker	Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5585401A (en) *	1994-12-09	1996-12-17	The Reents Of The University Of California	Method for enhancing outflow of aqueous humor in treatment of glaucoma
SE508609C2 (sv) *	1995-08-24	1998-10-19	Rural Patent Svenska Ab	Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
AU732508B2 (en) *	1996-01-26	2001-04-26	Governing Council Of The University Of Toronto, The	Nucleic acids and proteins related to Alzheimer's disease, and uses therefor
SE9604251L (sv)	1996-11-20	1997-12-22	Svenska Lantmaennen Riksfoerbu	Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) *	1998-12-17	2000-09-18	Rural Patent Svenska Ab	NASP-berikad äggula samt dess användning
CN1335887A (zh) *	1999-06-21	2002-02-13	印坎药物股份有限公司	血管抑制素∶一种Cys－Ser－Val－Thr－Cys－Gly特异性肿瘤细胞粘附受体
RU2192898C1 (ru) *	2001-08-16	2002-11-20	Московский научно-исследовательский институт глазных болезней им. Гельмгольца	Способ лечения герпетического кератита с изъязвлением
GB0322645D0 (en)	2003-09-26	2003-10-29	Melacure Therapeutics Ab	Use of antisecretory factor peptides
MX2008013777A (es) *	2006-04-27	2009-02-03	Lantmaennen As Faktor Ab	Usos medicos adicionales de la proteina antisecretora.
PL2015767T3 (pl) *	2006-04-27	2016-05-31	Lantmaennen As Faktor Ab	Zastosowanie czynnika przeciwwydzielniczego do leczenia nadciśnienia śródgałkowego
BRPI0710858A2 (pt) *	2006-04-27	2011-05-17	Lantmonnen As Faktor Ab	uso de uma proteìna anti-secretora, um derivado, homólogo e/ou fragmento da mesma, tendo atividade anti-secretora, e/ou um sal farmaceuticamente ativo da mesma

2007
- 2007-04-27 PL PL07748079T patent/PL2015767T3/pl unknown
- 2007-04-27 CN CN201210058790.XA patent/CN102633863B/zh not_active Expired - Fee Related
- 2007-04-27 DK DK12157100.4T patent/DK2468292T3/da active
- 2007-04-27 NZ NZ572255A patent/NZ572255A/en not_active IP Right Cessation
- 2007-04-27 BR BRPI0710959A patent/BRPI0710959B8/pt not_active IP Right Cessation
- 2007-04-27 CA CA2771087A patent/CA2771087C/en not_active Expired - Fee Related
- 2007-04-27 AU AU2007244004A patent/AU2007244004B2/en not_active Ceased
- 2007-04-27 ES ES12157100T patent/ES2773945T3/es active Active
- 2007-04-27 MX MX2008013769A patent/MX2008013769A/es active IP Right Grant
- 2007-04-27 RU RU2008146733/15A patent/RU2458703C2/ru active
- 2007-04-27 CN CN200780014996.XA patent/CN101432013B/zh not_active Expired - Fee Related
- 2007-04-27 EP EP12157100.4A patent/EP2468292B8/en active Active
- 2007-04-27 ES ES07748079.6T patent/ES2561945T3/es active Active
- 2007-04-27 NZ NZ598426A patent/NZ598426A/xx not_active IP Right Cessation
- 2007-04-27 KR KR1020087029053A patent/KR20090040404A/ko not_active Ceased
- 2007-04-27 PL PL12157100T patent/PL2468292T3/pl unknown
- 2007-04-27 WO PCT/SE2007/000414 patent/WO2007126364A2/en not_active Ceased
- 2007-04-27 EP EP07748079.6A patent/EP2015767B1/en not_active Not-in-force
- 2007-04-27 JP JP2009507632A patent/JP5284948B2/ja not_active Expired - Fee Related
- 2007-04-27 CA CA2650344A patent/CA2650344C/en not_active Expired - Fee Related
- 2007-04-27 SG SG201102876-8A patent/SG171602A1/en unknown
- 2007-04-27 DK DK07748079.6T patent/DK2015767T3/en active
2008
- 2008-10-22 IL IL194773A patent/IL194773A/en active IP Right Grant
- 2008-10-23 ZA ZA200809115A patent/ZA200809115B/xx unknown
- 2008-10-27 US US12/289,388 patent/US8207296B2/en not_active Expired - Fee Related
2012
- 2012-03-05 JP JP2012047547A patent/JP2012153695A/ja active Pending
- 2012-05-11 US US13/469,838 patent/US9000125B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU2007244004B2 (en)	2012-02-09
PL2468292T3 (pl)	2020-08-24
IL194773A0 (en)	2011-08-01
ES2561945T3 (es)	2016-03-01
RU2458703C2 (ru)	2012-08-20
CA2650344A1 (en)	2007-11-08
WO2007126364A8 (en)	2009-07-23
IL194773A (en)	2015-07-30
ES2773945T3 (es)	2020-07-15
NZ598426A (en)	2012-08-31
RU2008146733A (ru)	2010-06-10
BRPI0710959A2 (pt)	2012-02-28
EP2468292A1 (en)	2012-06-27
EP2468292B8 (en)	2020-02-26
KR20090040404A (ko)	2009-04-24
US8207296B2 (en)	2012-06-26
BRPI0710959B8 (pt)	2021-05-25
BRPI0710959B1 (pt)	2018-11-06
DK2015767T3 (en)	2016-02-08
JP5284948B2 (ja)	2013-09-11
JP2012153695A (ja)	2012-08-16
PL2015767T3 (pl)	2016-05-31
EP2015767A2 (en)	2009-01-21
WO2007126364A2 (en)	2007-11-08
CA2650344C (en)	2017-10-31
EP2015767B1 (en)	2016-01-06
SG171602A1 (en)	2011-06-29
WO2007126364A3 (en)	2008-03-06
JP2009535329A (ja)	2009-10-01
CN101432013B (zh)	2015-01-07
CN102633863A (zh)	2012-08-15
CA2771087A1 (en)	2007-11-08
NZ572255A (en)	2012-03-30
AU2007244004A1 (en)	2007-11-08
US20090162296A1 (en)	2009-06-25
MX2008013769A (es)	2009-02-03
US20120283191A1 (en)	2012-11-08
CN101432013A (zh)	2009-05-13
CN102633863B (zh)	2014-08-06
DK2468292T3 (da)	2020-03-23
ZA200809115B (en)	2009-07-29
US9000125B2 (en)	2015-04-07
EP2468292B1 (en)	2019-12-18

Legal Events

Date	Code	Title	Description
2012-03-02	EEER	Examination request
2022-12-08	MKLA	Lapsed	Effective date: 20210427

Publication	Publication Date	Title
CA2771087C (en)	2016-03-15	Use of antisecretory factors for treating intraocular hypertension
US8487074B2 (en)	2013-07-16	Modulation of lipid rafts
NZ572256A (en)	2012-02-24	Medical uses of antisecretory proteins for the treatment or prevention of dysfunction of lipid rafts, receptors and/or caveolae
AU2012201165B2 (en)	2013-12-19	New approach to treat intraocular hypertension
HK1172553A (en)	2013-04-26	New peptide having antisecretory activity
HK1172553B (en)	2021-01-08	New peptide having antisecretory activity
HK1128237B (en)	2014-09-26	Further medical uses of antisecretory protein